Acasti Pharma Current Ratio 2014-2024 | GRCE
Acasti Pharma current ratio from 2014 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Acasti Pharma Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-06-30 |
$0.02B |
$0.00B |
7.86 |
| 2024-03-31 |
$0.02B |
$0.00B |
14.26 |
| 2023-12-31 |
$0.03B |
$0.00B |
15.19 |
| 2023-09-30 |
$0.03B |
$0.00B |
20.68 |
| 2023-06-30 |
$0.02B |
$0.00B |
12.01 |
| 2023-03-31 |
$0.03B |
$0.00B |
8.59 |
| 2022-12-31 |
$0.03B |
$0.00B |
9.74 |
| 2022-09-30 |
$0.04B |
$0.00B |
9.86 |
| 2022-06-30 |
$0.04B |
$0.00B |
11.13 |
| 2022-03-31 |
$0.05B |
$0.00B |
13.89 |
| 2021-12-31 |
$0.05B |
$0.00B |
16.91 |
| 2021-09-30 |
$0.06B |
$0.00B |
12.19 |
| 2021-06-30 |
$0.06B |
$0.00B |
25.75 |
| 2021-03-31 |
$0.06B |
$0.00B |
39.50 |
| 2020-12-31 |
$0.03B |
$0.00B |
13.43 |
| 2020-09-30 |
$0.01B |
$0.00B |
3.66 |
| 2020-06-30 |
$0.01B |
$0.01B |
2.34 |
| 2020-03-31 |
$0.02B |
$0.01B |
2.50 |
| 2019-12-31 |
$0.02B |
$0.01B |
2.07 |
| 2019-09-30 |
$0.02B |
$0.01B |
1.81 |
| 2019-06-30 |
$0.02B |
$0.01B |
1.61 |
| 2019-03-31 |
$0.03B |
$0.01B |
2.05 |
| 2018-12-31 |
$0.04B |
$0.01B |
3.45 |
| 2018-09-30 |
$0.01B |
$0.01B |
0.56 |
| 2018-06-30 |
$0.01B |
$0.01B |
1.35 |
| 2018-03-31 |
$0.01B |
$0.01B |
1.42 |
| 2017-12-31 |
$0.01B |
$0.00B |
2.70 |
| 2017-09-30 |
$0.01B |
$0.00B |
1.73 |
| 2017-06-30 |
$0.01B |
$0.00B |
3.96 |
| 2017-02-28 |
$0.01B |
$0.00B |
4.54 |
| 2016-11-30 |
$0.01B |
$0.00B |
3.51 |
| 2016-08-31 |
$0.01B |
$0.00B |
5.75 |
| 2016-05-31 |
$0.01B |
$0.00B |
5.79 |
| 2016-03-31 |
$0.01B |
$0.00B |
5.79 |
| 2016-02-29 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.01B |
$0.00B |
9.11 |
| 2015-09-30 |
$0.01B |
$0.00B |
13.53 |
| 2015-06-30 |
$0.02B |
$0.00B |
8.30 |
| 2015-03-31 |
$0.02B |
$0.00B |
12.15 |
| 2014-12-31 |
$0.02B |
$0.00B |
10.61 |
| 2014-09-30 |
$0.02B |
$0.00B |
9.43 |
| 2014-06-30 |
$0.02B |
$0.00B |
12.99 |
| 2014-03-31 |
$0.03B |
$0.00B |
22.05 |
| 2014-02-28 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.01B |
$0.01B |
1.07 |
| 2013-09-30 |
$0.01B |
$0.00B |
1.30 |
| 2013-06-30 |
$0.01B |
$0.00B |
1.72 |
| 2013-03-31 |
$0.01B |
$0.00B |
2.40 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
